Cytokinetics ($CYTK) has experienced a significant shift in sentiment on biotwitter, going from a beloved company to one of the most criticized in just a short period. The change is attributed to the nature of its disease-modifying drug. CEO Robert Blum has denied any ongoing sales process but stated openness to evaluating options presented to the board. Speculation about Novartis acquiring Cytokinetics has been refuted, causing fluctuations in investor sentiment.
$CYTK It’s always about the M&A or lack thereof… Biotech investors have only one thing on their mind. https://t.co/ffr1weueMw
After being the center of speculation for several months, Cytokinetics’ CEO Robert Blum is putting the kibosh on the rumor that Novartis will be acquiring the biotech. $CYTK https://t.co/z0fLjFLVyZ
$CYTK some fast money exiting. Working out REMS takes time. I think CEO playing poker with the potential filing themselves.
$CYTK CEO Robert Blum on M&A speculation tonight, reiterated what he's said recently about the company not initiating a sales process or having a sales process underway. CYTK will evaluate any/all options that are presented to the board, he added. Also, business development is…
$cytk remarkable the sentiment shift on biotwitter in just 1 1/2 months. From darling to most hated biotech it seems. Only thing that has changed is that it's a disease-modifying drug. More to come. And no, dont expect offering when 2-year cash runway.